Skip to main content

Advertisement

Table 1 Demographic data of study subjects

From: Impaired lymph node stromal cell function during the earliest phases of rheumatoid arthritis

  Healthy control subjects (n = 14) Individuals with RA risk (n = 23) Patients with RA (n = 24)
Female sex, n (%) 9 (64) 20 (87) 17 (70)
Median age, years, (IQR) 29 (26–37) 49 (35–57) 56 (44–61)
IgM-RF-positive, n (%) 0 (0) 10 (43) 20 (3–107)
IgM-RF level, kU/L, median (IQR) 20 (3–107) 131 (31–309)
ACPA-positive, n (%) 0 (0) 13 (57) 18 (75)
Median ACPA level, kAU/L (IQR) 43 (4–177) 115 (21–924)
IgM-RF and ACPA both positive, n (%) 0 (0) 0 (0) 14 (58)
Median DAS28, (IQR) 5 (1–10)c
Median ESR, mm/h (IQR) 7 (2–10) 11 (5–27)b
Median CRP, mg/L (IQR) 0.5 (0.3–1.2)c 1.6 (0.9–3.2) 4.6 (1.4–13)d
Median TJC68 (IQR) 0 (0) 1.5 (0–4.5) 9 (4–20)e
Median SJC68 (IQR) 0 (0) 0 (0) 5 (1–10)d
Treatment, n (%)    9 (39)
 Corticosteroids    6 (26)
 NSAIDs    4 (17)f
 DMARDs    5 (22)
 Failed TNF inhibitor therapy    5 (22)
  1. Abbreviations: RA Rheumatoid arthritis, IgM-RF immunoglobulin M rheumatoid factor, kU/L kilo Unit/L, ACPA anti-citrullinated protein antibodies, kAU/L kilo arbitrary Unit, ESR erythrocyte sedimentation rate, CRP C-reactive protein, TJC68 68-joint tender joint count, SJC68 68-joint swollen joint count, NSAID non-steroidal anti-inflammatory drug, DMARD disease-modifying antirheumatic drug, DAS28 disease activity score in 28 joints, TNF tumour necrosis factor
  2. a Levels missing from one individual
  3. b Levels missing from two individuals
  4. c Levels missing from six individuals
  5. d Levels missing from seven individuals
  6. e Levels missing from five individuals
  7. f Treatment unknown for five individuals